» Articles » PMID: 30897158

Structural Determination of the Complement Inhibitory Domain of Borrelia Burgdorferi BBK32 Provides Insight into Classical Pathway Complement Evasion by Lyme Disease Spirochetes

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2019 Mar 22
PMID 30897158
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The carboxy-terminal domain of the BBK32 protein from Borrelia burgdorferi sensu stricto, termed BBK32-C, binds and inhibits the initiating serine protease of the human classical complement pathway, C1r. In this study we investigated the function of BBK32 orthologues of the Lyme-associated Borrelia burgdorferi sensu lato complex, designated BAD16 from B. afzelii strain PGau and BGD19 from B. garinii strain IP90. Our data show that B. afzelii BAD16-C exhibits BBK32-C-like activities in all assays tested, including high-affinity binding to purified C1r protease and C1 complex, and potent inhibition of the classical complement pathway. Recombinant B. garinii BGD19-C also bound C1 and C1r with high-affinity yet exhibited significantly reduced in vitro complement inhibitory activities relative to BBK32-C or BAD16-C. Interestingly, natively produced BGD19 weakly recognized C1r relative to BBK32 and BAD16 and, unlike these proteins, BGD19 did not confer significant protection from serum killing. Site-directed mutagenesis was performed to convert BBK32-C to resemble BGD19-C at three residue positions that are identical between BBK32 and BAD16 but different in BGD19. The resulting chimeric protein was designated BXK32-C and this BBK32-C variant mimicked the properties observed for BGD19-C. To query the disparate complement inhibitory activities of BBK32 orthologues, the crystal structure of BBK32-C was solved to 1.7Å limiting resolution. BBK32-C adopts an anti-parallel four-helix bundle fold with a fifth alpha-helix protruding from the helical core. The structure revealed that the three residues targeted in the BXK32-C chimera are surface-exposed, further supporting their potential relevance in C1r binding and inhibition. Additional binding assays showed that BBK32-C only recognized C1r fragments containing the serine protease domain. The structure-function studies reported here improve our understanding of how BBK32 recognizes and inhibits C1r and provide new insight into complement evasion mechanisms of Lyme-associated spirochetes of the B. burgdorferi sensu lato complex.

Citing Articles

Unprecedented genetic variability of PFam54 paralogs among Eurasian Lyme borreliosis-causing spirochetes.

Wulbern J, Windorfer L, Sato K, Nakao M, Hepner S, Margos G Ecol Evol. 2024; 14(5):e11397.

PMID: 38779535 PMC: 11109050. DOI: 10.1002/ece3.11397.


Multifunctional interaction of CihC/FbpC orthologs of relapsing fever spirochetes with host-derived proteins involved in adhesion, fibrinolysis, and complement evasion.

Damm A, Reyer F, Langhoff L, Lin Y, Falcone F, Kraiczy P Front Immunol. 2024; 15:1390468.

PMID: 38726006 PMC: 11079166. DOI: 10.3389/fimmu.2024.1390468.


Inhibition of the C1s Protease and the Classical Complement Pathway by 6-(4-Phenylpiperazin-1-yl)Pyridine-3-Carboximidamide and Chemical Analogs.

Xu X, Herdendorf T, Duan H, Rohlik D, Roy S, Zhou H J Immunol. 2023; 212(4):689-701.

PMID: 38149922 PMC: 10872613. DOI: 10.4049/jimmunol.2300630.


nymph saliva protein blocks host inflammation and complement-mediated killing of Lyme disease agent, .

Bencosme-Cuevas E, Kim T, Nguyen T, Berry J, Li J, Adams L Front Cell Infect Microbiol. 2023; 13:1253670.

PMID: 37965264 PMC: 10641286. DOI: 10.3389/fcimb.2023.1253670.


Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease.

Grazlewska W, Holec-Gasior L Antibodies (Basel). 2023; 12(4).

PMID: 37873860 PMC: 10594444. DOI: 10.3390/antib12040063.


References
1.
McDowell J, Tran E, Hamilton D, Wolfgang J, Miller K, Marconi R . Analysis of the ability of spirochete species associated with relapsing fever, avian borreliosis, and epizootic bovine abortion to bind factor H and cleave c3b. J Clin Microbiol. 2003; 41(8):3905-10. PMC: 179811. DOI: 10.1128/JCM.41.8.3905-3910.2003. View

2.
Hallstrom T, Siegel C, Morgelin M, Kraiczy P, Skerka C, Zipfel P . CspA from Borrelia burgdorferi inhibits the terminal complement pathway. mBio. 2013; 4(4). PMC: 3747585. DOI: 10.1128/mBio.00481-13. View

3.
Seshu J, Boylan J, Gherardini F, Skare J . Dissolved oxygen levels alter gene expression and antigen profiles in Borrelia burgdorferi. Infect Immun. 2004; 72(3):1580-6. PMC: 356058. DOI: 10.1128/IAI.72.3.1580-1586.2004. View

4.
Kraiczy P, Skerka C, Brade V, Zipfel P . Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun. 2001; 69(12):7800-9. PMC: 98876. DOI: 10.1128/IAI.69.12.7800-7809.2001. View

5.
Kurtenbach K, Sewell H, Ogden N, Randolph S, Nuttall P . Serum complement sensitivity as a key factor in Lyme disease ecology. Infect Immun. 1998; 66(3):1248-51. PMC: 108041. DOI: 10.1128/IAI.66.3.1248-1251.1998. View